How big is Aclaris Therapeutics, Inc.?

As of Jun 18, Aclaris Therapeutics, Inc. has a market capitalization of 151.59 million, with net sales of 17.79 million and a net profit of -130.22 million over the last four quarters. The company reported shareholder's funds of 155.55 million and total assets of 220.33 million as of Dec 24.

Market Cap: As of Jun 18, Aclaris Therapeutics, Inc. has a market capitalization of 151.59 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Aclaris Therapeutics, Inc. reported net sales of 17.79 million and a net profit of -130.22 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 155.55 million and total assets of 220.33 million.

What does Aclaris Therapeutics, Inc. do?

Aclaris Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for immuno-inflammatory diseases. As of March 2025, it reported net sales of $1 million and a net loss of $15 million, with a market cap of $151.59 million.

Overview:<BR>Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company focused on developing small molecule therapies for immuno-inflammatory diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 151.59 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.73 <BR>Return on Equity: -29.83% <BR>Price to Book: 1.05<BR><BR>Contact Details:<BR>Address: 640 Lee Rd Ste 200, WAYNE PA: 19087-5636 <BR>Tel: 1 484 3247933 <BR>Fax: 1 302 6555049 <BR>Website: https://www.aclaristx.com/

Should I buy, sell or hold Aclaris Therapeutics, Inc.?

Who are in the management team of Aclaris Therapeutics, Inc.?

As of March 2022, Aclaris Therapeutics, Inc.'s management team includes Dr. Neal Walker as President and CEO, along with independent directors Mr. Vincent Milano, Dr. Maxine Gowen, Mr. William Humphries, Dr. Anand Mehra, and Mr. Christopher Molineaux.

As of March 2022, the management team of Aclaris Therapeutics, Inc. includes Dr. Neal Walker, who serves as the President, Chief Executive Officer, Co-Founder, and Director. Additionally, the Board of Directors comprises Mr. Vincent Milano, Dr. Maxine Gowen, Mr. William Humphries, Dr. Anand Mehra, and Mr. Christopher Molineaux, all of whom hold independent director positions.

Is Aclaris Therapeutics, Inc. overvalued or undervalued?

As of March 12, 2018, Aclaris Therapeutics, Inc. is considered risky and overvalued, with a Price to Book Value of 1.15 and a P/E ratio of -4.8751, making it less attractive compared to peers like Evolus, Inc. and the S&P 500.

As of 12 March 2018, the valuation grade for Aclaris Therapeutics, Inc. moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 1.15, an EV to Sales ratio of 3.42, and an EV to Capital Employed of 1.55. <BR><BR>In comparison to peers, Aclaris has a P/E ratio of -4.8751, while Evolus, Inc. has a P/E of -8.2365, indicating that Aclaris is less attractive in terms of valuation among its peers. The negative returns of Aclaris reinforce its overvaluation stance, especially when considering the lack of positive returns compared to the S&P 500.

Is Aclaris Therapeutics, Inc. technically bullish or bearish?

As of August 8, 2025, Aclaris Therapeutics shows a mildly bullish trend with positive weekly indicators, despite mixed signals from daily moving averages and a year-to-date underperformance compared to the S&P 500.

As of 8 August 2025, the technical trend for Aclaris Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and Bollinger Bands are mildly bullish. However, the daily moving averages and OBV are mildly bearish, indicating some mixed signals. The stock has shown a 1-month return of 5.41%, outperforming the S&P 500's 2.33% return, but it has underperformed significantly on a year-to-date basis with a return of -21.37% compared to the S&P 500's 12.22%. Overall, the current stance is mildly bullish, supported by the positive momentum in the weekly indicators.